Sionna Therapeutics vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Sionna Therapeutics is developing next-generation small molecule CFTR modulators targeting full restoration of CFTR protein function in cystic fibrosis patients; raised $170M+ total;
About
Sionna Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Lexington, Massachusetts. The company was founded with a focus on discovering and developing next-generation treatments for cystic fibrosis (CF) — a life-threatening genetic disease caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene that impair the protein's ability to regulate fluid transport in the lungs, digestive tract, and other organs. While Vertex Pharmaceuticals' Trikafta has transformed CF treatment for patients with the most common mutation (F508del), Sionna aims to develop modulators that more fully restore CFTR function and address patient segments not adequately covered by existing drugs.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Sionna Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.